Comparison of human immunodeficiency virus type 1 tropism profiles in clinical samples by the Trofile and MT-2 assays.
The recent availability of CCR5 antagonists as anti-human immunodeficiency virus (anti-HIV) therapeutics has highlighted the need to accurately identify CXCR4-using variants in patient samples when use of this new drug class is considered. The Trofile assay (Monogram Biosciences) has become the method that is the most widely used to define tropism in the clinic prior to the use of a CCR5 antagonist. By comparison, the MT-2 assay has been used since early in the HIV epidemic to define tropism in clinical specimens. Given that there are few data from direct comparisons of these two assays, we evaluated the performance of the plasma-based Trofile assay and the peripheral blood mononuclear cell (PBMC)-based MT-2 assay for the detection of CXCR4 use in defining the tropism of HIV isolates derived from clinical samples. The various samples used for this comparison were derived from participants of the Amsterdam Cohort Studies on HIV infection and AIDS who underwent consecutive MT-2 assay testing of their PBMCs at approximately 3-month intervals. This unique sample set was specifically selected because consecutive MT-2 assays had demonstrated a shift from negative to positive in PBMCs, reflecting the first emergence of CXCR4-using virus in PBMCs above the level of detection of the assay in these individuals. Trofile testing was performed with clonal HIV type 1 (HIV-1) variants (n = 21), MT-2 cell culture-derived cells (n = 20) and supernatants (n = 42), and plasma samples (n = 76). Among the clonal HIV-1 variants and MT-2 cell culture-derived samples, the results of the Trofile and MT-2 assays demonstrated a high degree of concordance (95% to 98%). Among consecutive plasma samples, detection of CXCR4-using virus was at or before the time of first detection by the MT-2 assay in 5/10 patients by the original Trofile assay and in 9/10 patients by the enhanced-sensitivity Trofile assay. Differences in the time to the first detection of CXCR4 use between the MT-2 assay (PBMCs) and the original Trofile assay (plasma) were greatly reduced by the enhanced-sensitivity Trofile assay, suggesting that sensitivity for the detection of minor CXCR4-using variants may be a more important determinant of discordant findings than compartmentalization. The similarities in performance of the enhanced-sensitivity Trofile and MT-2 assays suggest that either may be an appropriate methodology to define tropism in patient specimens.
Coakley
Eoin
E
Monogram Biosciences, Clinical Research, South San Francisco, California, USA.
Reeves
Jacqueline D
JD
Huang
Wei
W
Mangas-Ruiz
Marga
M
Maurer
Irma
I
Harskamp
Agnes M
AM
Gupta
Soumi
S
Lie
Yolanda
Y
Petropoulos
Christos J
CJ
Schuitemaker
Hanneke
H
van 't Wout
Angélique B
AB
D015497:HIV-1 / Q000502:physiology*; D006801:Humans; D007963:Leukocytes, Mononuclear / Q000821:virology*; D010949:Plasma / Q000821:virology*; D019718:Receptors, CXCR4 / Q000502:physiology; D056189:Viral Tropism
C527276:CXCR4 protein, human; D019718:Receptors, CXCR4
J Virol. 1998 Jun;72(6):5099-107
9573281
J Infect Dis. 2005 Aug 1;192(3):466-74
15995960
Ann Intern Med. 1993 May 1;118(9):681-8
8096374
J Clin Microbiol. 1994 Sep;32(9):2291-4
7814561
J Infect Dis. 1994 May;169(5):968-74
7909549
J Virol. 1992 May;66(5):3183-7
1560543
Nat Med. 1999 Mar;5(3):344-6
10086394
J Virol. 1988 Jun;62(6):2026-32
3130494
Science. 1996 May 10;272(5263):872-7
8629022
J Infect Dis. 1996 Feb;173(2):349-54
8568295
Proc Natl Acad Sci U S A. 1997 Mar 4;94(5):1925-30
9050881
Nature. 1998 Jan 15;391(6664):240
9440686
J Clin Invest. 2000 Oct;106(8):1039-52
11032864
J Infect Dis. 2007 Jul 15;196(2):304-12
17570119
Science. 1996 Jun 28;272(5270):1955-8
8658171
J Virol. 1988 Nov;62(11):4414-9
2459416
J Infect Dis. 2006 Oct 1;194(7):926-30
16960780
Nat Protoc. 2008;3(3):363-70
18323807
J Infect Dis. 2005 Mar 15;191(6):866-72
15717260
Antimicrob Agents Chemother. 2007 Feb;51(2):566-75
17116663
J Infect Dis. 1993 Dec;168(6):1374-9
7902382
Nat Med. 1997 Mar;3(3):338-40
9055864
J Immunol. 1998 Oct 1;161(7):3702-10
9759895
N Engl J Med. 2008 Oct 2;359(14):1429-41
18832244
AIDS. 1998 May 7;12(7):729-36
9619804
J Virol. 2007 Oct;81(19):10232-41
17652386
Clin Infect Dis. 2007 Feb 15;44(4):591-5
17243065
J Acquir Immune Defic Syndr. 2005 Nov 1;40(3):267-75
16249699
Proc Natl Acad Sci U S A. 2000 Feb 1;97(3):1269-74
10655520
Virology. 1989 Jul;171(1):149-55
2472701
J Virol. 1997 Oct;71(10):7478-87
9311827
J Virol. 2001 Nov;75(21):10455-9
11581413
AIDS. 2008 Jul 31;22(12):1411-5
18614863
Nature. 1996 Jun 20;381(6584):661-6
8649511
J Virol. 1992 Nov;66(11):6777-80
1404617
AIDS. 1992 Jan;6(1):49-54
1543566
J Virol. 1997 Apr;71(4):2705-14
9060623
Nature. 1996 Jun 20;381(6584):667-73
8649512
J Infect Dis. 2009 Dec 1;200(11):1724-8
19874179
J Infect Dis. 2006 Jul 15;194(2):238-46
16779731